Valproate

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only
Half-life: 9–16 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: valproate · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Inhibits UGT; could raise psilocin levels in theory.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: 9–16 h (FDA label, checked 2026-09-30)

Evidence types on this record

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

UGT inhibition (theoretical effect on psilocin levels): Inhibits UGT enzymes (glucuronidation), the main route by which the body clears psilocin. In theory this could raise psilocin levels or lengthen the effect. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Seizure disorder or bipolar disorder (possible indications)CO 2.5(A)(2)

05 Sources

Valproate — prescribing information · FDA label (DailyMed)

Report an error in this record →